Needle-Free hope: ultrasound may spot dangerous liver pressure
NCT ID NCT07365709
First seen Jan 31, 2026 · Last updated Jun 23, 2026 · Updated 16 times
Summary
This study tests whether a combination of contrast-enhanced ultrasound and spleen stiffness measurement can accurately detect high blood pressure in the liver (portal hypertension) in people with cirrhosis. Currently, doctors must insert a catheter into a neck vein to measure this pressure, which is uncomfortable and risky. If the non-invasive methods work well, they could replace the invasive test. The study will enroll 107 adults with cirrhosis and compare the ultrasound results to the standard invasive measurement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SonoVue (sulphur hexafluoride microbubbles)
What this could lead to
If successful, this could provide a safe, non-invasive alternative to the current invasive test for diagnosing portal hypertension in cirrhosis patients.
What could go wrong
This is an early-stage diagnostic study with only 107 participants, so results may not apply to all patients. The new methods may not be accurate enough to replace the gold standard test.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.